Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook

Stock Track

30 Jan

Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.

The key factors driving the stock's soar were:

1. Strong Q4 Revenue and Earnings Growth
Teva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.

2. Continued Momentum in 2025 Guidance
For 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.

3. Promising Pipeline and Strategic Focus
Teva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1147676754"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147676754\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1147676754?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-30 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147676754","market":"hk","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook","media":"Stock Track","content":"<html><body><p>Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.</p>\n<p>The key factors driving the stock's soar were:</p>\n<p>1. <b>Strong Q4 Revenue and Earnings Growth</b><br/>\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.</p>\n<p>2. <b>Continued Momentum in 2025 Guidance</b><br/>\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.</p>\n<p>3. <b>Promising Pipeline and Strategic Focus</b><br/>\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical's Stock Soars 5.18% on Strong Q4 Results and Optimistic 2025 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-01-30 09:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.</p>\n<p>The key factors driving the stock's soar were:</p>\n<p>1. <b>Strong Q4 Revenue and Earnings Growth</b><br/>\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.</p>\n<p>2. <b>Continued Momentum in 2025 Guidance</b><br/>\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.</p>\n<p>3. <b>Promising Pipeline and Strategic Focus</b><br/>\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1147676754","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147676754","pubTimestamp":1738200531,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical Industries Ltd.  saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.Teva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher op","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"股票轨迹梯瓦制药(Teva Pharmaceutical)股价因强劲的第四季度业绩和乐观的2025年前景而飙升5.18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock price surge 5.18% on Wednesday after reporting better-than-expected fourth quarter 2024 results and providing an optimistic outlook for 2025.\nThe key factors driving the stock's soar were:\n1. Strong Q4 Revenue and Earnings Growth\nTeva reported Q4 2024 revenue of $4.23 billion, up 7% year-over-year, driven by robust growth in its key innovative products AUSTEDO, UZEDY, and AJOVY, as well as growth in its generics business across all regions. The company's non-GAAP earnings per share of $0.71 beat analyst estimates, aided by higher operating income.\n2. Continued Momentum in 2025 Guidance\nFor 2025, Teva forecasts revenue of $16.8 billion to $17.4 billion, representing growth of 2% to 5% compared to 2024. The company expects its innovative portfolio, including AUSTEDO, AJOVY, and UZEDY, to maintain strong momentum, offsetting slower growth in its generics business. Teva's non-GAAP earnings per share guidance of $2.35 to $2.65 also exceeded analyst expectations.\n3. Promising Pipeline and Strategic Focus\nTeva highlighted its promising pipeline, including the potential of its anti-TL1A drug duvakitug for multiple indications, as well as its dual-action rescue inhaler and olanzapine LAI programs. The company also reaffirmed its strategic focus on driving growth through its innovative products, launching complex generics and biosimilars, and improving operational efficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}